{
    "clinical_study": {
        "@rank": "42091", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine,\n      fluorouracil-uracil and leucovorin in treating patients who have advanced cancer that has\n      not responded to previous therapy."
        }, 
        "brief_title": "Combination Chemotherapy In Treating Patients With Advanced Cancer", 
        "completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "condition": "Unspecified Adult Solid Tumor, Protocol Specific", 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the maximum tolerated doses of gemcitabine, fluorouracil-uracil (UFT), and\n           leucovorin calcium in patients with advanced refractory cancer.\n\n        -  Assess the toxicity of this combination regimen in this patient population.\n\n        -  Evaluate this regimen in terms of response rate, response duration, and overall\n           survival in these patients.\n\n      OUTLINE: This is a dose escalation study of gemcitabine and fluorouracil-uracil.\n\n      Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients receive oral\n      leucovorin calcium immediately followed by oral fluorouracil-uracil (UFT) three times a day\n      on days 1-21. Courses are repeated every 28 days. Treatment continues in the absence of\n      disease progression or unacceptable toxicity.\n\n      Cohorts of 3-6 patients receive escalating doses of gemcitabine and UFT until the maximum\n      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2\n      of 6 patients experience dose limiting toxicities.\n\n      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed malignancy refractory to existing\n             chemotherapy or for which no standard therapy exists\n\n          -  Evaluable disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  SWOG 0-2\n\n        Life expectancy:\n\n          -  Greater than 3 months\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count greater than 1,500/mm3\n\n          -  Platelet count greater than 100,000/mm3\n\n          -  Hemoglobin greater than 8.0 mg/dL\n\n        Hepatic:\n\n          -  Bilirubin less than 2.0 mg/dL\n\n          -  AST less than 3.0 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Other:\n\n          -  No active infection requiring antibiotics\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective barrier contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  At least 3 weeks since prior systemic cytotoxic chemotherapy (including fluorouracil)\n             and recovered\n\n          -  No prior gemcitabine\n\n        Endocrine therapy:\n\n          -  Prior hormonal therapy allowed\n\n          -  No concurrent hormonal contraception\n\n        Radiotherapy:\n\n          -  At least 3 weeks since prior radiotherapy to large areas of active bone marrow and\n             recovered\n\n        Surgery:\n\n          -  Prior major surgery allowed and recovered\n\n        Other:\n\n          -  No prior or concurrent antiviral nucleosides"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003925", 
            "org_study_id": "CDR0000067112", 
            "secondary_id": [
                "P30CA022453", 
                "WSU-D-1641", 
                "WSU-04-28-98-M02-FB", 
                "NCI-G99-1526"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "leucovorin calcium", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "tegafur-uracil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tegafur", 
                "Gemcitabine", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "keyword": "unspecified adult solid tumor, protocol specific", 
        "lastchanged_date": "April 5, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/WSU-D-1641"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Detroit", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48201-1379"
                }, 
                "name": "Barbara Ann Karmanos Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin", 
        "overall_official": {
            "affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "last_name": "Philip A. Philip, MD, PhD, FRCP", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003925"
        }, 
        "results_reference": [
            {
                "PMID": "17414457", 
                "citation": "El-Rayes BF, Zalupski M, Shields AF, Manza SG, LoRusso P, Philip PA. A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin. Am J Clin Oncol. 2007 Apr;30(2):101-5."
            }, 
            {
                "PMID": "10442378", 
                "citation": "Philip PA, Ibrahim D, Zalupski M, Arlauskas P, Shields A. Gemcitabine and UFT plus oral calcium folinate: phase I study. Oncology (Huntingt). 1999 Jul;13(7 Suppl 3):116-9."
            }
        ], 
        "source": "Barbara Ann Karmanos Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Barbara Ann Karmanos Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Barbara Ann Karmanos Cancer Institute": "42.331 -83.046"
    }
}